Arix Bioscience: $29M Series A for PreciThera
Summary
Arix Biosciences Investment Manager, Daniel OConnell, MD, PhD, will join PreciTheras Board of Directors.Proceeds of the Series A financing will be used to develop novel molecules and to advance PreciTheras lead candidate through IND and into clinical studies with the goal to establish clinical proof of concept and identify a path to registration.PreciThera is focusing on orphan bone diseases that cannot be treated via traditional protein replacement therapies. Prior to PreciThera, Dr. Crine founded Enobia Pharma, which advanced its lead product, asfotase alfa, into clinical development for treatment of the orphan bone disease hypophosphatasia. Headquartered in and with an office in , Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.For further information, please visit www.arixbioscience.comPreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. Understanding of novel biology will allow PreciTheras targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients.For further information, please visit www.precithera.com